Vasculitides are a group of disorders characterised by inflammation and necrosis of the walls of blood vessels, resulting in narrowing or occlusion of the vessel lumen, leading to ischaemia and destruction of the tissues. They are usually classified according to the size of the vessels predominantly involved. The nomenclature of vasculitides was revised in 2012 at the second international Chapel Hill Consensus Conference (CHCC2012) to reflect the advances in our understanding of vasculitis. A wide range of immunopathological mechanisms have been implicated in the aetiology of vasculitis, and a subset of small‐vessel vasculitides are strongly associated with antineutrophil cytoplasmic antibodies (ANCA). The clinical presentation, often involving multiple organ systems, is heterogenous and depends on the size and site of the vessels involved. This makes both classification and diagnosis of these disorders challenging. Management of these conditions is fraught with the difficulty of balancing the benefits of immunosuppression with toxicity. However, with improved understanding of the immunopathogenesis, earlier diagnoses and newer targeted treatment options, improvements in morbidity and mortality have been reported.
Key Concepts
Vasculitis may be ‘idiopathic’ or ‘primary’ but it is important to rule out common mimics of vasculitis and the many underlying conditions that can induce a ‘secondary’ vasculitis.
Vasculitides are usually classified according to the predominant size of the vessels involved, but there is ongoing debate as to the most accurate and clinically useful way to classify the conditions.
Immunopathological mechanisms are diverse, with roles for both humoral and cellular immune mechanisms.
A subset of small‐vessel vasculitides are strongly associated with antineutrophil cytoplasmic antibody (ANCA), and this is often used as a biomarker to aid diagnosis.
There is strong evidence for a pathogenic role of ANCA in the ‘ANCA associated vasculitides’, but the extent of this continues to be debated.
Vasculitis is usually considered a ‘systemic’ disease with the propensity to affect blood vessels throughout the body, but individual clinical presentations may be limited to specific organ systems.
Many patients initially experience a prodrome of nonspecific symptoms such as malaise, fatigue, fever, night sweats or weight loss.
The prevalence of vasculitis is increasing. This may be due to the increased rates of diagnosis, due to clinical suspicion and use of biomarkers such as ANCA; increased survival postdiagnosis or a true increased incidence.
Further research into the underlying pathological processes is vital to identifying potential treatment targets.
Many trials are currently in progress and will contribute to the improving rates of morbidity and mortality in systemic vasculitis.